HUSCAP logo Hokkaido Univ. logo

Hokkaido University Collection of Scholarly and Academic Papers >
Hokkaido University Hospital >
Peer-reviewed Journal Articles, etc >

Baseline serum angiopoietin-2 and VEGF levels predict the deterioration of the liver functional reserve during lenvatinib treatment for hepatocellular carcinoma

This item is licensed under:Creative Commons Attribution 4.0 International

Files in This Item:

The file(s) associated with this item can be obtained from the following URL:

Title: Baseline serum angiopoietin-2 and VEGF levels predict the deterioration of the liver functional reserve during lenvatinib treatment for hepatocellular carcinoma
Authors: Shigesawa, Taku Browse this author
Suda, Goki Browse this author →KAKEN DB
Kimura, Megumi Browse this author
Maehara, Osamu Browse this author
Tokuchi, Yoshimasa Browse this author
Kubo, Akinori Browse this author
Yamada, Ren Browse this author
Furuya, Ken Browse this author
Baba, Masaru Browse this author
Kitagataya, Takashi Browse this author
Suzuki, Kazuharu Browse this author
Ohara, Masatsugu Browse this author
Kawagishi, Naoki Browse this author
Nakai, Masato Browse this author
Sho, Takuya Browse this author
Natsuizaka, Mitsuteru Browse this author
Morikawa, Kenichi Browse this author
Ogawa, Koji Browse this author
Sakamoto, Naoya Browse this author
Issue Date: 1-Mar-2021
Publisher: PLOS
Journal Title: PLoS ONE
Volume: 16
Issue: 3
Start Page: e0247728
Publisher DOI: 10.1371/journal.pone.0247728
Abstract: A deteriorated liver functional reserve during systemic therapy for unresectable hepatocellular carcinoma (HCC) causes poor patient outcomes. We aimed to identify predictive factors associated with the deterioration of Child-Pugh score at 8 weeks after lenvatinib initiation. Patients with adequate clinical data and baseline preserved serum samples available were included. Baseline fibroblast growth factor (FGF)19 and 21, angiopoietin (ANG)2, and vascular endothelial growth factor (VEGF) levels were evaluated. Thirty-seven patients were included, and 6, 15, 14, and 2 experienced complete response, partial response, stable disease, and progressive disease, respectively. Twenty-four (65%) and 13 (35%) patients showed a maintained/improved and deteriorated Child-Pugh-score, respectively. While baseline clinical data, treatment response, and laboratory data were similar between these two patient groups, baseline ANG2 and VEGF levels were significantly higher (P = 0.0017) and lower (P = 0.0231), respectively, in patients with deteriorated Child-Pugh score than in those without. Based on receiver operating characteristic curve analysis, cut-off values for ANG2 and VEGF were found to be 3,108 pg/mL and 514.9 pg/mL, respectively. Among patients with low VEGF and high ANG2, 89% (8/9) exhibited a deteriorated Child-Pugh score, whereas none of the patients (0/9) with high VEGF and low ANG2 did. The deterioration of the Child-Pugh score in patients with unresectable HCC who are treated with lenvatinib may be predictable based on combined baseline serum ANG2 and VEGF levels.
Type: article
Appears in Collections:北海道大学病院 (Hokkaido University Hospital) > 雑誌発表論文等 (Peer-reviewed Journal Articles, etc)

Export metadata:

OAI-PMH ( junii2 , jpcoar_1.0 )

MathJax is now OFF:


 - Hokkaido University